Therapeutic Asset Ratings

395 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Sacituzumab Tirumotecan Prostate Cancer	Virginia Commonwealth University	P2	CC (46)
Shr-1701 Prostate Cancer	Fudan University	P2	CC (46)
srf617 Prostate Cancer	Coherus Oncology, Inc.	P2	CC (46)
Tocilizumab Prostate Cancer	David Oh	P2	CC (46)
Trastuzumab Deruxtecan Prostate Cancer	AstraZeneca	P2	CC (46)
Triadeno Vaccine Prostate Cancer	National Cancer Institute (NCI)	P2	CC (46)
VOLITINIB Prostate Cancer	Canadian Cancer Trials Group	P2	CC (46)
Zimberelimab Prostate Cancer	Coherus Oncology, Inc.	P2	CC (46)
Pegargiminase Prostate Cancer	M.D. Anderson Cancer Center	P1/2	CC (46)
Tinengotinib Prostate Cancer	Memorial Sloan Kettering Cancer Center	P1/2	CC (46)
AZD1775 Prostate Cancer	Canadian Cancer Trials Group	P2	CC (45)
Recombinant Ephb4-Hsa Fusion Protein Prostate Cancer	Northwestern University	P2	CC (45)
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMAN MONOCLONAL REGN2810 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL REGN2810 .KAPPA.-CHAIN, DIMER Prostate Cancer	M.D. Anderson Cancer Center	P1/2	CC (45)
Nezastomig Prostate Cancer	M.D. Anderson Cancer Center	P1/2	CC (45)
Shr-4394 Prostate Cancer	Jiangsu HengRui Medicine Co., Ltd.	P1/2	CC (45)
FDHT F-18 Prostate Cancer	Memorial Sloan Kettering Cancer Center	P1	CC (44)
BICARBONATE ION Prostate Cancer	University of Washington	P1/2	CC (44)
Masofaniten Prostate Cancer	Pedro Barata, MD, MSc	P2	CC (43)
Pacritinib Prostate Cancer	Medical College of Wisconsin	P2	CC (42)
H-gamma1 heavy chain Homo sapiens (1-447) [VH (Homo sapiens IGHV4-5901 (99.0%) -(IGHD) -IGHJ302 (93.3%) T125>I (114), CDR-IMGT [8.7.11] (26-33.51-57.96-106)) (1-117) -Homo sapiens IGHG101, G1m17,1 CH1 K120, CH3 D12, L14, 9-G1v21 CH2 Y15.1, T16, E18 (CH1 K120 (214) (118-215), hinge 1-15 (216-230), CH2 M15.1>Y (252), S16>T (254), T18>E (256) (231-340), CH3 D12 (356), L14 (358) (341-445), CHS (446-447)) (118-447)], (220-214')-disulfide with L-kappa light chain Homo sapiens (1'-214') [V-KAPPA (Homo sapiens IGKV3-1101 (96.8%) -IGKJ401 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC01 (100%) Km3 A45.1, V101 (CKAPPA A45.1 (153'), V101 (191')) (108'-214')]; dimer (226-226'':229-229'')-bisdisulfide, produced in a cell line derived from Chinese hamster ovary (CHO) cells, glycoform alfa Prostate Cancer	Kineta Inc.	P1/2	CC (42)
Copanlisib Prostate Cancer	Memorial Sloan Kettering Cancer Center	P1/2	CC (41)
[ 161 tb]tb psma i&t Prostate Cancer	Peter MacCallum Cancer Centre, Australia	P1/2	CC (40)
[177Lu] Lu-XT033 Prostate Cancer	Sinotau Pharmaceutical Group	P1/2	CC (40)
177Lu-rhPSMA-10.1 Prostate Cancer	M.D. Anderson Cancer Center	P1/2	CC (40)
18f-flt Prostate Cancer	University of Wisconsin, Madison	P1/2	CC (40)

Showing 201 to 225 of 395 assets

PreviousPage 9 of 16Next